Lexicon Pharmaceuticals
LXRX
#7142
Rank
C$0.70 B
Marketcap
C$1.93
Share price
-1.41%
Change (1 day)
112.21%
Change (1 year)

P/E ratio for Lexicon Pharmaceuticals (LXRX)

P/E ratio as of December 2025 (TTM): -7.34

According to Lexicon Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -7.34211. At the end of 2024 the company had a P/E ratio of -1.16.

P/E ratio history for Lexicon Pharmaceuticals from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
2024-1.16-39.54%
2023-1.91-38.92%
2022-3.13-51.52%
2021-6.463.87%
2020-6.22-282.8%
20193.40-158.91%
2018-5.77-28.7%
2017-8.10-19.78%
2016-10.1-96.21%
2015-2665602.54%
2014-4.67-48.13%
2013-9.00-10.41%
2012-10.0

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Eterna Therapeutics
ERNA
-0.0167-99.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
16.6-326.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Ultragenyx Pharmaceutical
RARE
-6.19-15.63%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
19.5-366.09%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
33.1-550.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Esperion Therapeutics
ESPR
-6.82-7.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Illumina
ILMN
28.9-493.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Ligand Pharmaceuticals
LGND
78.0-1,162.54%๐Ÿ‡บ๐Ÿ‡ธ USA
Aerie Pharmaceuticals
AERI
-20.3 176.94%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.